Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01231919 · ClinicalTrials.gov registry record · Phase 1
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT01231919: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01231919 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 45 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01231919, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or leukemia. MK2206 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
The MTD will be the maximum dose at which fewer than one-third of patients experience DLT during course 1 of therapy.
Interventions
- OTHER pharmacological study
- OTHER diagnostic laboratory biomarker analysis
- DRUG Akt inhibitor MK2206
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2011-01 |
| Phase | Phase 1 |
What the finished NCT01231919 record still lists
NCT01231919 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 3 interventions - of which pharmacological study is the first listed.
NCT01231919 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01231919 about?
NCT01231919 is a clinical study titled "MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia". This phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or leukemia. MK2206 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01231919?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2011-01.
What interventions are being tested in trial NCT01231919?
The interventions under investigation include: pharmacological study (OTHER), diagnostic laboratory biomarker analysis (OTHER), Akt inhibitor MK2206 (DRUG).
Who is sponsoring clinical trial NCT01231919?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01231919's enrollment target sits among peer trials
45 1066th of 2000 higher than 915 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia